Abdur Rahaman Shaikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdur Rahaman Shaikh has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Munmun Koley
Department of Homeopathy, East Bishnupur State Homoeopathic Dispensary, Chandi Daulatabad Block Primary Health Centre, South 24 Parganas, West Bengal, Under the Department of Health and Family Welfare, Government of West Bengal, India
3 shared publications - Priyanka Ghosh
Dept. of Organon of Medicine and Homoeopathic Philosophy, D. N. De Homoeopathic Medical College and Hospital, Govt. of West Bengal, 12, Gobinda Khatick Road, Tangra, Kolkata 700046, West Bengal, India
3 shared publications - Shyamal Kumar Mukherjee
Dept. of Community Medicine, D. N. De Homoeopathic Medical College and Hospital, Govt. of West Bengal, 12, Gobinda Khatick Road, Tangra, Kolkata 700046, West Bengal, India
3 shared publications - Subhranil Saha
Department of Repertory, D. N. De Homeopathic Medical College and Hospital, Government of West Bengal, affiliated to The West Bengal University of Health Sciences, Kolkata, West Bengal, India
3 shared publications - Pulakendu Bhattacharya
Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
2 shared publications - Sabir Ahamed
Department of Surgery, D. N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India
2 shared publications
Latest Publications
- 16 October 2023
- Published by Georg Thieme Verlag KG in Homœopathic Links
- Vol. 36 (04) , 281-286
A Randomized Trial of Three Homeopathic Drugs: Rauwolfia serpentina, Viscum album, and Spartium scoparium in Essential Hypertension
Hypertension (HTN) remains one of the major risk factors for heart failure, stroke, and coronary heart disease worldwide. This study was undertaken to compare the antihypertensive effects produced by the mother tinctures (MTs) of three homeopathic drugs—Rauwolfia serpentina (RS), Viscum album (VA), and Spartium scoparium (SS; also known as Cytisus scoparius [CS]) in essential hypertension. This open-label, randomized, three parallel arm, pragmatic, pilot trial was conducted on 60 participants with essential hypertension in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Participants were randomized into three groups: RS, VA, and SS equally. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at baseline and after 30 and 60 minutes. Group differences at different time points and overall were measured using one-way analysis of variance (ANOVA) and three-way repeated measure ANOVA models, respectively, after adjusting for baseline differences using intention-to-treat approaches. A p value less than 0.05 was considered statistically significant. Endpoint analysis included 60 participants. Although the highest mean reductions in SBP and DBP with time were achieved in the RS group, all three medicines revealed similar antihypertensive effects without any significant differences (SBP: F 2, 57 = 1.710, p = 0.190; DBP: F 2, 57 = 0.732, p = 0.485). No harm or serious adverse events were reported from either of the groups. All three medicines (RS, VA, and SS) produced similar antihypertensive effects in essential hypertension. Trial registration: CTRI/2021/02/031548; UTN: U1111–1264–6856. D.M., S.M., and S.K.M. were responsible for concept development and literature search. D.M., S.M., A.R.S., S.A., and P.G. contributed to clinical study and data acquisition. P.G., M.K., and S.S. were responsible for the concept, study design, data interpretation, statistical analysis, and preparation of the article. All the authors reviewed and approved the final version of the article. The data that support the findings of this study are available from the corresponding author upon reasonable request. Article published online: 16 October 2023 © 2023. Thieme. All rights reserved. Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 16 October 2023
- Published by Georg Thieme Verlag KG in Homœopathic Links
- Vol. 36 (04) , 281-286
A Randomized Trial of Three Homeopathic Drugs: Rauwolfia serpentina, Viscum album, and Spartium scoparium in Essential Hypertension
Hypertension (HTN) remains one of the major risk factors for heart failure, stroke, and coronary heart disease worldwide. This study was undertaken to compare the antihypertensive effects produced by the mother tinctures (MTs) of three homeopathic drugs—Rauwolfia serpentina (RS), Viscum album (VA), and Spartium scoparium (SS; also known as Cytisus scoparius [CS]) in essential hypertension. This open-label, randomized, three parallel arm, pragmatic, pilot trial was conducted on 60 participants with essential hypertension in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Participants were randomized into three groups: RS, VA, and SS equally. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at baseline and after 30 and 60 minutes. Group differences at different time points and overall were measured using one-way analysis of variance (ANOVA) and three-way repeated measure ANOVA models, respectively, after adjusting for baseline differences using intention-to-treat approaches. A p value less than 0.05 was considered statistically significant. Endpoint analysis included 60 participants. Although the highest mean reductions in SBP and DBP with time were achieved in the RS group, all three medicines revealed similar antihypertensive effects without any significant differences (SBP: F 2, 57 = 1.710, p = 0.190; DBP: F 2, 57 = 0.732, p = 0.485). No harm or serious adverse events were reported from either of the groups. All three medicines (RS, VA, and SS) produced similar antihypertensive effects in essential hypertension. Trial registration: CTRI/2021/02/031548; UTN: U1111–1264–6856. D.M., S.M., and S.K.M. were responsible for concept development and literature search. D.M., S.M., A.R.S., S.A., and P.G. contributed to clinical study and data acquisition. P.G., M.K., and S.S. were responsible for the concept, study design, data interpretation, statistical analysis, and preparation of the article. All the authors reviewed and approved the final version of the article. The data that support the findings of this study are available from the corresponding author upon reasonable request. Article published online: 16 October 2023 © 2023. Thieme. All rights reserved. Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 25 September 2023
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 113 (03) , 158-166
Individualized Homeopathic Medicines in the Treatment of Knee Osteoarthritis: Double-Blind, Randomized, Placebo-Controlled Feasibility Trial
Introduction This study aimed at examining the feasibility issues of comparing individualized homeopathic medicines (IHMs) with identical-looking placebos for treating knee osteoarthritis (OA). Methods Forty eligible patients participated in this double-blind, randomized (1:1), placebo-controlled feasibility trial in the outpatient clinics of a homeopathic hospital in West Bengal, India. Either IHMs or identical-looking placebos were administered, along with mutually agreed-upon concomitant care guidelines. The Knee Injury and Osteoarthritis Outcome Score (KOOS) was the primary outcome measure, along with derived Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores from KOOS. The EQ-5D-5L questionnaire and Visual Analog Scale (VAS) were the secondary outcomes. All were measured at baseline and after 2 months. Group differences and effect sizes (Cohen's d) were estimated using an intention-to-treat approach. p-Values less than 0.05 (two-tailed) were considered statistically significant. Results Enrolment/screening and trial retention rates were 43% and 85% respectively. Recruitment was difficult owing to the coronavirus disease 2019 (COVID-19) lockdown. Group differences were statistically significant, favoring IHMs against placebos in all the KOOS sub-scales: symptoms (p < 0.001), pain (p = 0.002), activities of daily living (p < 0.001), sports or recreation (p = 0.016), and quality of life (p = 0.002). Derived WOMAC scores from KOOS favored IHMs against placebos: stiffness (p < 0.001) and pain (p < 0.001). The EQ-5D-5L questionnaire score (p < 0.001) and EQ-5D-5L VAS scores (p < 0.001) also yielded significant results, favoring IHMs over placebos. All the effect sizes ranged from moderate to large. Sulphur was the most frequently prescribed homeopathic medication. Neither group reported any harm or serious adverse events. Conclusion Although recruitment was sub-optimal due to prevailing COVID-19 conditions during the trial, the action of IHMs was found to be superior to that of placebos in the treatment of knee OA. Larger and more definitive studies, with independent replications, are warranted in order to substantiate the findings. Trial registration: CTRI/2021/02/031453.
- 25 September 2023
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 113 (03) , 158-166
Individualized Homeopathic Medicines in the Treatment of Knee Osteoarthritis: Double-Blind, Randomized, Placebo-Controlled Feasibility Trial
Introduction This study aimed at examining the feasibility issues of comparing individualized homeopathic medicines (IHMs) with identical-looking placebos for treating knee osteoarthritis (OA). Methods Forty eligible patients participated in this double-blind, randomized (1:1), placebo-controlled feasibility trial in the outpatient clinics of a homeopathic hospital in West Bengal, India. Either IHMs or identical-looking placebos were administered, along with mutually agreed-upon concomitant care guidelines. The Knee Injury and Osteoarthritis Outcome Score (KOOS) was the primary outcome measure, along with derived Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores from KOOS. The EQ-5D-5L questionnaire and Visual Analog Scale (VAS) were the secondary outcomes. All were measured at baseline and after 2 months. Group differences and effect sizes (Cohen's d) were estimated using an intention-to-treat approach. p-Values less than 0.05 (two-tailed) were considered statistically significant. Results Enrolment/screening and trial retention rates were 43% and 85% respectively. Recruitment was difficult owing to the coronavirus disease 2019 (COVID-19) lockdown. Group differences were statistically significant, favoring IHMs against placebos in all the KOOS sub-scales: symptoms (p < 0.001), pain (p = 0.002), activities of daily living (p < 0.001), sports or recreation (p = 0.016), and quality of life (p = 0.002). Derived WOMAC scores from KOOS favored IHMs against placebos: stiffness (p < 0.001) and pain (p < 0.001). The EQ-5D-5L questionnaire score (p < 0.001) and EQ-5D-5L VAS scores (p < 0.001) also yielded significant results, favoring IHMs over placebos. All the effect sizes ranged from moderate to large. Sulphur was the most frequently prescribed homeopathic medication. Neither group reported any harm or serious adverse events. Conclusion Although recruitment was sub-optimal due to prevailing COVID-19 conditions during the trial, the action of IHMs was found to be superior to that of placebos in the treatment of knee OA. Larger and more definitive studies, with independent replications, are warranted in order to substantiate the findings. Trial registration: CTRI/2021/02/031453.
- 19 September 2022
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 112 (02) , 085-096
Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial
Introduction Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU. Methods This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed. Results The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F 1, 56 = 13.833, p 1, 56 = 32.982, p 1, 56 = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups. Conclusion IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU. Trial registration CTRI/2019/10/021503; UTN: U1111–1241–1431. The trial was conducted as part of the postgraduate thesis of the corresponding author. P.G., S.G., S.K.M., S.D. and A.R.S. contributed to the literature search, study concept, conducting the trial, data collection, data evaluation and drafting the manuscript. S.S.A., N.K.S., P.B., M.K., and S.S. contributed to study design, data interpretation, statistical analysis, and drafting of the manuscript. All the authors reviewed and approved the final manuscript for submission. Received: 25 November 2021 Accepted: 22 March 2022 Article published online: 19 September 2022 © 2022. Faculty of Homeopathy. This article is published by Thieme. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 19 September 2022
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 112 (02) , 085-096
Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial
Introduction Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU. Methods This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed. Results The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F 1, 56 = 13.833, p 1, 56 = 32.982, p 1, 56 = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups. Conclusion IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU. Trial registration CTRI/2019/10/021503; UTN: U1111–1241–1431. The trial was conducted as part of the postgraduate thesis of the corresponding author. P.G., S.G., S.K.M., S.D. and A.R.S. contributed to the literature search, study concept, conducting the trial, data collection, data evaluation and drafting the manuscript. S.S.A., N.K.S., P.B., M.K., and S.S. contributed to study design, data interpretation, statistical analysis, and drafting of the manuscript. All the authors reviewed and approved the final manuscript for submission. Received: 25 November 2021 Accepted: 22 March 2022 Article published online: 19 September 2022 © 2022. Faculty of Homeopathy. This article is published by Thieme. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany